Don't Expect to See a Lot More PCSK9 Inhibitor Rxs

May 2017

You'll hear buzz about using the PCSK9 inhibitors, Repatha (evolocumab) or Praluent (alirocumab), in patients with CV disease.

These injectable meds lower LDL cholesterol by about 60%...but we've been waiting to see if they improve CV outcomes.

Now evidence suggests that adding Repatha to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote